Jeffrey L. Port, M.D.

Thoracic Surgery
Jeffrey Port

"The Diagnosis of cancer can be overwhelming. At Cornell, we utilize a multidiciplinary team approach in the treatment of patients with lung and esophageal cancers. Our dedicated team is involved from the initial evaluation through the completion of a patient's post-operative course. This unparalleled attention to the patient helps to ease the burden of the diagnosis. For those of us involved in research as well as care, this is a very important time -- several novel treatment approaches recently have been developed here at Cornell, and we currently are showing promising results."

As an attending thoracic surgeon at Weill Cornell Medical Center, Dr Port has developed an interest in minimally invasive approaches to the diagnosis, staging and treatment of thoracic malignancies. He has have recently integrated Endobronchial Ultrasound (EBUS) and Electromagnetic Navigational Bronchoscopy (ENB) into the thoracic surgical program. These techniques offer a minimally invasive approach to lung cancer diagnosis and staging. Dr. Port specializes in lung and esophageal cancers, mediastinal tumors and Barrett's Esophagus. He also specializes in the area of minimally invasive thoracoscopic pulmonary surgery. Dr. Port has taken a leadership role on the development of the robotic surgical program and now offers robotic surgical approaches for mediastinal, lung and esophageal disorders.

Dr. Port has authored numerous journal articles and book chapters on the treatment of lung and esophageal cancer. He has been selected as a best doctor in New York Magazine for 2012.

Dr. Port resides with his family here in Manhattan.


Rated One of New York Magazine's Best Doctors.


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA [Medicare]
  • Aetna - Weill Cornell [POS]
  • Affinity Essential
  • Affinity Health Plan
  • Blue Priority Network
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield [Pathway X]
  • Empire Blue Cross/Blue Shield [Pathway X Enhanced]
  • Empire Blue Cross/Blue Shield [PPO]
  • Empire Blue Cross/Blue Shield [EPO]
  • Empire Blue Cross/Blue Shield [HMO]
  • Empire Blue Cross/Blue Shield [Mediblue (Senior)]
  • Fidelis Care
  • GHI [CBP]
  • Health First
  • Health Insurance Plan of NY (HIP) [Medicare]
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) [Medicaid]
  • Health Plus - Amerigroup [CHP]
  • Health Plus - Amerigroup
  • Health Republic
  • Medicaid
  • Medicare
  • Oscar
  • Oxford Health Plans [Medicare Advantage]
  • Oxford Health Plans [Liberty]
  • Oxford Health Plans [Freedom]
  • Rockefeller University - CoreSource
  • UHC Compass
  • United Health Care [Medicare]
  • United Health Care
  • United Health Care [Community Plan]
  • VNSNY CHOICE Medicare [Medicare]
  • VNSNY CHOICE Medicare [HMO]




1.Ellis J, Ng B, Port JL, Burt M. Isolated lung perfusion with carboplatin for metastatic sarcoma in the F344 rat. Surg Forum 1994; 45:294-7.

2. Wang HY, Ng B, Blumberg D, Port JL, Hochwald SN, Burt M. Pulmonary artery perfusion of doxorubicin with blood flow occlusion: pharmacokinetics and treatment in an experimental metastatic sarcoma model in the rat. Ann Thoracic Surg 1995; 60:1390-4.

3. Ng B, Lenert JT Weksler B, Port JL, Ellis J, Burt M. Isolated lung perfusion with 2-deoxy-5flourouridine (FUDR) is an effective treatment for colorectal adenocarcinoma lung metastases in the BDIX rat. Ann Thoracic Surg 1995; 59:205-8.

4. Port JL, Hochwald SN, Wang HY, Burt M. Buthionine sulfoximine pretreatment potentiates the effect of isolated lung perfusion with doxorubicin. Ann Thoracic Surg 1995; 60:239-44.

5. Blumberg D, Port JL, Weksler B, Delgado R, Rosai J, Bains MS, Ginsberg RJ, Martini N, McCormack PM, Rusch V, Burt M. Thymoma: a multivariate analysis of factors predicting survival. Ann Thoracic Surg 1995; 60:908-13.

6. Harrison LE, Port JL, Hochwald SN, Blumberg D, Burt M. Perioperative growth hormone improves wound healing and immunologic function in rats receiving adriamycin. J Surg Res 1995; 58: 646-50.

7. Wang HY, Port JL, Hochwald SN, Burt M. Revised technique of isolated lung perfusion in the rat. Ann Thoracic Surg 1995; 60: 211-2.

8. Wang HY, Hochwald SN, Port JL, Harrison L, Burt M. Hypoglycemia with Glycerol salvage: a role in anti-neoplastic therapy. Anticancer Res 1995; 15:1343-8

9. Port JL, Ng, B, Ellis H, Nawata S, Lenert JT, Burt M. Isolated lung perfusion with FUDR in the rat: pharmacokinetics and survival. Ann Thoracic Surg 1996; 62:848-52.

10. Hochwald SN, Harrison LE, Port JL, Blumberg D, Brennan MF, Burt M. Depletion of high energy phosphate compounds in the tumor bearing state and reversal following tumor resection. Surgery 1996; 120: 534-41.

11. Kent MS, Flieder DF, Port JL, Altorki NK. Proliferative myositis: A rare pseudosarcoma of the chest wall. Ann of Thor Surg 2002 Apr;73(4):1296-1298

12. Altorki NK, Kent MS, Ferrara CA, Port JL, Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Annals of Surgery, 2002 Aug; 236(2):177-183.

13. Port JL, Kent M, Altorki NK. Early lung cancer detection and treatment strategies. J Surgical Onc. 2002 Dec; 11(4):191-9.

14. Port JL, Kent M, Korst RJ, Bacchetta M, Altorki NK. Thoracic Esophageal Perforations: A Decade of Experience. Ann Thor Surg. 2003 Apr;75(4):1071-4.

15. Bachetta MD, Korst RJ, Altorki NK, Port JL, Isom OW, Mack CA. Resection of a symptomatic pericardial cyst using the computer-enhanced da Vinci Surgical System. Ann Thorac Surg. 2003 Jun; 75(6):1953-5.

16. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Flieder DB, Ferrara CA, Yankelevitz DF, Subramanian K, Pasmantier MW, Dannenberg AJ. Celecoxib, a selective COX-2 inhibitor, enhances the response to preoperative Paclitaxel/Carboplatin in early stage lung cancer. J Clinical Onc, 2003 Jul 15; 21(14):2645-50.

17. Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK: Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a phase II trial. J Thorac Cardiovasc Surg. 2003; 126(5):1603-8.

18. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK: Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thor Surg. 2004; 77(1):254-9; discussion 259.

19. Port JL, Kent MS, Korst RJ, Libby D, Pasmantier M, Altorki NK: Tumor size predicts survival within stage IA non-small cell lung cancer. Chest. 2003 Nov; 124(5):1828-33.

20. Kent MS, Port JL, Altorki NK. Current state of imaging for lung cancer staging. Thorac Surg Clin. 2004 Feb: 14(1):1-13.

21. Kent MS, Korst RJ, Gayle LB, Port JL, Altorki NK: A simple solution for management of the postpneumonectomy empyema cavity. Ann Thorac Surg. 2004; 78(3):1107-8.

22. Port JL, Kent M, Korst RJ, Lee PC, Levin MA, Flieder D, Altorki NK Surgical resection for lung cancer in the octogenarian. Chest.2004 Sep; 126(3):733-8.

23. Port JL, Yamaguchi K, Du B, De Lorenzo M, Chang M, Heerdt PM, Kopelovich L, Marcus CB, Altorki NK, Subramanian K, Dannenberg AJ: Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis. 2004; 25(11):2275-81.

24. Korst RJ, Gold HT, Kent MS, Port JL, Lee PC, Altorki NK: Surveillance computed tomography after complete resection for non-small cell lung cancer: results and costs. J. Thorac Cardiovasc Surg. 2005; 129(3):652-60.

25. Port JL, Korst RJ, Lee PC, Levin MA, Becker DE, Keresztes, R, Altorki NK: Surgical resection for residual N2 Disease following induction chemotherapy. Ann Thorac Surg. 2005 May; 79(5)1686-90.

26. Altorki NK, Port JL, Zhang F, Golijanin D, Thaler HT, Duffield-Lillico AJ, Subramanian K, Dannenberg AJ: Chemotherapy induces the expression of Cyclooxygenase-2 in non-small cell lung cancer. Clin Cancer Res. 2005 Jun 1; 11(11):4191-7.

27. Korst RJ, Port JL, Lee PC, Altorki NK: Intrathoracic manifestations of cervical anastomotic leaks after transthoracic esophagectomy for carcinoma. Ann Thorac Surg. 2005 Oct; 80(4):1185-90.

28. Flieder DB, Port JL, Korst RJ, Christos PJ, Levin MA, Becker DE, Altorki NK: Tumor size is a determinant of stage distribution of t1 non-small cell lung cancer. Chest. 2005 Oct; 128(4):2304-8.

29. Kent MS, Korn P, Port JL, Lee, PC, Altorki NK, Korst RJ: Cost- effectiveness of chest computed tomography following lung cancer resection: A decision analysis model. Ann Thorac Surg. 2005 Oct; 80(4):1215-22; discussion 1222-3.

30. Port JL, Andrade RS, Levin MA Korst RJ, Lee PC, Becker DE, Altorki NK: Positron emission tomographic scanning in the diagnosis and staging of non-small cell lung cancer 2 cm in size or less. J Thorac Cardiovasc Surg. 2005 Dec; 130(6):1611-5.

31. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D: VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005 Dec 8; 438 (7069):820-7.

32. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK: Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006 Aug; 82(2):480-4; discussion 484-5.

33. Korst RJ, Kansler AL, Port JL, Lee PC, Altorki NK: Accuracy of surveillance computed tomography in detecting recurrent or new primary lung cancer in patients with completely resected lung cancer. Ann Thorac Surg. 2006 Sep; 82(3):1009-15; discussion 1015.

34. Lee PC, Korst RJ, Port JL, Kerem Y, Kansler AL, Altorki NK: Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size. J Thorac Cardiovasc Surg. 2006 Dec; 132(6):1382-9. Epub 2006 Oct 30.

35. Port JL, Korst RJ, Lee PC, Kansler AL, Kerem Y, Altorki NK: Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? Ann Thorac Surg. 2007 Feb;83(2):397-400.

36. Kim AW, Korst RJ, Port JL, Altorki NK, Lee PC. Giant cavernous hemangioma of the distal esophagus treated with esophagectomy. J Thorac Cardiovasc Surg. 2007Jun;133(6):1665.

37. Lee PC, Port JL, Korst RJ, Liss Y, Meherally DN, Altorki NK. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2007 Jul;84(1):177-81.

38. Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P, Mazumdar M, Altorki NK. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg. 2007 Aug;84(2):393-400.

39. Huston JM, King H, Maresh A, Liska D, Port JL, Altorki NK, Lee PC. Hernia of Morgagni: case report. J Thorac Cardiovasc Surg 2008; 135(1):212-3.

40. Sica G, Vazquez MF, Altorki N, Port J, Lee PC, Liu Y, Hyjek E, Saqi A. PAX-5 expression in pulmonary neuroendocrine neoplasms: Its usefulness in surgical and fine-needle aspiration biopsy specimens. Am J Clin Pathol. 2008;129(4):556-62.

41. Altorki NK, Lee PC, Liss Y, Meherally D, Korst RJ, Christos P, Mazumdar M, Port JL. Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg. 2008; 247(3):434-9.

42. Wagner PL, Tam W, Lau PY, Port JL, Paul S, Altorki N,K, Lee PC. Primary esophageal large T-cell lymphoma mimicking esophageal carcinoma: a case report and literature review. J Thorac Cardiovac Surg. 2008; 135(4):957-8, 958 el.

43. Servais E, Paul S, Port JL, Altorki NK, Lee PC. Carcinoid tumor nested within a bronchogenic cyst. J Thorac Cardiovasc Surg. 2008 Jul;136(1):227-8.

44. Altorki NK, Zhou XK, Stiles B, Port JL, Paul S, Lee PC, Mazumdar M. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008 Aug; 248(2):221-6.

45. Hughes D, Otani T, Yang P, Newman RA, Yantiss RK, Altorki NK, Port JL, Yan M, Markowitz SD, Mazumdar M, Tai HH, Subbaramaiah K, Dannenberg AJ. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer. Cancer Prev Res (Phila) 2008 Sep;1(4):241-9.

46. Abrams JA, Lee PC, Port JL, Altorki NK, Neugut AI. Cigarette smoking and risk of lung metastasis from esophageal cancer. Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2707-13.

47. Sica G, Wagner PL, Altorki N, Port J, Lee PC, Vazquez MF, Saqi A. Immunohistochemical expression of estrogen and progesterone receptors in primary pulmonary neuroendocrine tumors. Arch Pathol Lab Med. 2008 Dec;132(12):1889-95.

48. Stiles BM, Servais EL, Lee PC, Port JL, Paul S, Altorki N. Point: Clinical stage 1A non-small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic 1A non-small cell lung cancer: the problem of understaging. J Thorac Cardiovasc Surg. 2009 Jan;137(1):13-9.

49. Paul S, L:ee, PC, Altorki NK, Stiles BM, Port JL. Partial upper sternotomy for aterosuperior mediastinal surgery: An institutional experience. Ann Surg Oncol. 2009 Apr;16(4):1039-42. Epub 2009 Feb 5.

50. Wagner PL, Hyjek E, Vazquez MF, Meherally D, Liu YF, Chadwick PA, Rengifo T, Sica GL, Port JL, Lee PC, Paul S, Altorki NK, Saqi A. CXCL12 and CXCR4 in adenocarcinoma of the lung: association with metastasis and survival. J Thorac Cardiovasc Surg. 2009 March;137(3):615-21.

51. Paul S, Altorki NK, Stiles BM, Port JL, Lee PC. Surgical management of chylothorax. Thorac Cardiovasc Surg. 2009 Jun;57(4):226-8. Epub 2009 May 20.

52. Lee PC, Port JL, Paul S, Stiles BM, Altorki NK. Predictors of long-term survival after resection of esophageal carcinoma with nonregional nodal metastases. Ann Thorac Surg. 2009 Jul;88(1):186-92; discussion 192-3.

53. Paul S, Altorki NK, Stiles BM, Port JL, Lee PC. Images in cardiothoracic surgery. A case of severe heartburn. Ann Thorac Surg. 2009 Jun; 87(6):1959.

54. Lee BE, Port JL, Stiles BM, Saunders J, Paul S, Lee PC, Altorki N. TNM stage is the most important determinant of survival in metachronous lung cancer. Ann Thorac Surg. 2009 Oct;88(4):1100-5.

55. Stiles BM, Christos P, Port JL, Lee PC, Paul S, Saunders J, Altorki NK. Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. J Thorac Cardiovasc Surg. 2010 Feb;139(2):387-94.Epub 2009 Dec 1

56. Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, Onaitis MW, Stiles BM, Port JL, D'Amico TA. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg. 2010 Feb;139(2):366-78.

57. Stiles BM, Mirza F, Port JL, Lee PC, Paul S, Christos P, Altorki NK. Predictors of cervical and recurrent laryngeal lymph node metastases from esophageal cancer. Ann Thorac Surg. 2010 Dec;90(6):1805-11.

58. Paul S, Mirza F, Port JL, Lee PC, Stiles BM, Kansler AL, Altorki NK. Survival of patients with clinical stage IIIA non-small cell ling cancer after induction therapy: Age, mediastinal downstaging and extent of pulmonary resection as independent predictors. J Thorac Cardiovasc Surg. 2011 Jan;141(1):48-58 Epub 2010

59. Lee PC, Mirza FM, Port JL, Stiles BM, Paul S, Christos P, Altorki NK. Predictors of recurrence and disease-free survival in patients with completely resected esophageal carcinoma. J Thorac Cardiovasc Surg. 2011May;141(5):1196-206. Epub 2011 Mar 12.

60. Altorki NK, Christos P, Port JL, Lee PC, Mirza F, Spinelli C, Keresztes R, Beneck D, Paul S, Stiles BM, Zhang Y, Schrump DS. Preoperative Taxane-Based Chemotherapy and Celecoxib for Carcinoma of the Esophagus and Gastroesophageal Junction: Results of a Phase 2 Trial. J Thorac Oncol. 2011 Jun;6(6):1121-7.

61. Sharaiha RZ, Halazun KJ, Mirza F, Port JL, Lee PC, Neugut AI, Altorki NK, Abrams JA. Elevated Preoperative Neutrophil:Lymphocyte Ratio as a Predictor of Postoperative Disease Recurrence in Esophageal Cancer. Ann Surg Oncol. 2011 Nov;18(12):3362-9. Epub 2011 May6

62. Stiles BM, Mirza F, Coppolino A, Port JL, Lee PC, Paul S, Altorki NK. Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease. Ann Thorac Surg. 2011 Aug;92(2):491-6; discussion 496-8. Epub 2011 Jun 24.

63. Parashar B, Wernicke, AG, Pavese A, Prabhsimranjot S, Trichter S, Sabbas A, Kutler DI, Kuhel W, Port JL, Lee PC, Dattatreyudu N, Clifford Chao KS. Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff. American Brachytherapy Society 2011 Jun 1. [Epub ahead of print].

64. Port JL, Mirza FM, Lee PC, Paul S, Stiles BM, Altorki NK. Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery. Ann Thorac Surg 2011Dec;92(6):1951-7. Epub 2011 Oct 7

65. Stiles BM, Mirza F, Towe CW, Ho VP, Port JL, Lee PC, Paul S, Yankelevitz D, Altorki NK. Cumulative Radiation Dose From Medical Imaging Procedures in Patients Undergoing Resection for Lung Cancer Ann Thorac Surg. 2011;92(4):1170-9. Epub 2011 Jul 13.

66. Paul S, Mirza FM, Nasar A, Port JL, Lee PC, Stiles BM, Nguyen AB, Sedrakyan A, Altorki NK. Prevalence, outcomes, and a risk-benefit analysis of diaphragmatic hernia admissions: An examination of the National Inpatient Sample database. J Thorac Cardiovasc Surg. 2011 Oct;142(4):747-54. Epub 2011 Jul 30.

67. Gao D, Joshi N, Choi H, Ryu S, Hahn M, Catena R, Sadik H, Argani P, Wagner PL, Vahdat LT, Port JL, Stiles B, Sukumar S, Altorki NK, Rafii S, Mittal V. Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition. Cancer Res. 2012 Mar 15;72(6):1384-94. Epub 2012 Jan 26

68. Paul S, Nasar A, Port JL, Lee PC, Stiles BC, Nguyen AB, Altorki NK, Sedrakyan A. Comparative Analysis of Diaphragmatic Hernia Repair Outcomes Using the Nationwide Inpatient Sample Database. Arch Surg. 2012 Mar 19. [Epub ahead of print]

69. Stiles BM, Nasar A, Mirza FA, Lee PC, Paul S, Port JL, Altorki NK. Worldwide Oesophageal Cancer Collaboration guidelines for lymphadenectomy predict survival following neoadjuvant therapy. Eur J Cardiothorac Surg. 2012 Apr 4. [Epub ahead of print]


Books, Book Chapters and Reviews

1. Port JL, Burt M, Surgical resection of pulmonary metastases. In: Regional Therapy of Advanced Cancer. Lotze MT, Rubin JT, Editors. JB Lippincott, Philadelphia 1995.

2. Port JL, Ginsberg RJ. Surgical Resection of Stage I and II Lung Cancer In: Lung Cancer. Pass HI, Mitchell JB, Johnson JH, Turrisi AT Editors. Lippincott-Raven, Philadelphia 1999.

3. Port JL, Altorki, NK. Ivor Lewis Esophagectomy. In: Current Therapy in Thoracic and Cardiovascular Surgery. Cameron DE. W.B. Saunders, Philadelphia 2001.

4. Port JL, Ginsberg RJ. Surgical Management of Thymoma. In: Chest Surgery Clinics of North America. Kirschner PA. W.B. Saunders, Philadelphia 2001.

5. Kent M, Port JL, Altorki NK. Esophagectomy for Esophageal Cancer. In: Clinical Gastroenterology: An Internist's Illustrated Guide to GI Surgery. Wu GY, Aziz K. Humana Press, Inc, 2003.

6. Kent M, Port JL. Superior Vena Cava Syndrome. In: Oncology: An Evidence-Based Approach. Springer Press, 2006.

7. Stiles BM, Port JL, Altorki NK. "Screening for Lung Cancer." Surgery of the Chest, 8th ed. Sabiston & Spencer, ed., 2008

8. Altorki NK, Zhou K, Stiles B, Port JL, Paul S, Lee, PC, Mazumdar M. Extended Resection for Esophageal Carcinoma. In: Shields TW, ed. General Thoracic Surgery, 7th edition. Lippincott Williams & Wilkins, 2008.

9. Castillo MD, Port JL, Heerdt PM. Thoracic Surgery in the Elderly, in Slinger, Principles and Practice of Anesthesia for Thoracic Surgery, Springer Chapter 25, 2011 (in press)

Honors and Awards

Alpha Omega Alpha NYU School of Medicine 1991

Best Doctors in New York Magazine 2012